Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency
Our retrospective study highlights that acute use of nirmatrelvir/ritonavir significantly reduces the risk of post-acute sequelae of SARS-CoV-2 infection (long COVID) in immunodeficient patients, emphasizing the need for clinical trials that include this high-risk population.
Authors
- Mei‐Sing Ong (ORCID: https://orcid.org/0000-0002-1241-1013)
- Karen M. Gilbert (ORCID: https://orcid.org/0000-0002-3297-0250)
- Henry Ssemaganda (ORCID: https://orcid.org/0009-0001-2877-3465)
- Jocelyn R. Farmer (ORCID: https://orcid.org/0000-0003-4901-9848)
- Neha V. Khairnar (ORCID: https://orcid.org/0009-0000-9187-6734)
- Mostafa Aglan (ORCID: https://orcid.org/0000-0002-5849-1223)
- Aditi Jogdand (ORCID: https://orcid.org/0000-0001-8483-7219)
Institutions
- Boston Children's Hospital (US)
- Lahey Hospital and Medical Center (US)
- Lahey Medical Center (US)
- Harvard Pilgrim Health Care (US)
- Boston Children's Museum (US)
Publication Details
- Journal
- Journal of Human Immunity
- Published
- 2025-10-21
- DOI
- https://doi.org/10.70962/jhi.20250107
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute on Minority Health and Health Disparities